Journal
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
Volume 10, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fcell.2022.931132
Keywords
lung adenocarcinoma; sialyltransferase; prognostic analysis; ST3GAL6; ST3GAL6-AS1
Categories
Funding
- National Natural Science Foundation of China
- Shanghai Sailing Program [82172001, 81902968]
- Plan of Clinical Specialty Construction in Shanghai Putuo District Health System [19YF1456900]
- Clinical Research Special Project of Shanghai Municipal Health Commission [2020tszk02]
- Shanghai Municipal Science and Technology Major Project [20214Y0495]
- Shanghai Science and Technology Committee
- [20S11901400]
Ask authors/readers for more resources
The downregulation of ST3GAL6 in lung adenocarcinoma (LUAD) is associated with advanced stage and poor clinical outcomes. Its deficiency promotes invasiveness of LUAD cells through the activation of EGFR/MAPK signaling pathway.
Sialylation aberration has been implicated in lung cancer development by altering signaling pathways. Hence, it is urgent to identify key sialyltransferases in the development of lung adenocarcinoma (LUAD), which is a common malignant subtype of non-small cell lung cancer. Herein, by systematically investigating the expression levels of ST3GAL family members in several public databases, we consistently found the frequent downregulation of ST3GAL6 in LUAD samples. Its downregulation is significantly negatively associated with stage, and significantly reduced in proximal-proliferative molecular subtype and predicts poor clinical outcomes. By protein-protein interaction network analysis and validation, we found that ST3GAL6 deficiency promotes LUAD cell invasiveness with the activated EGFR/MAPK signaling, accompanied by the elevated expression levels of matrix metalloproteinases 2 and 9, which can be partially reversed by EGFR inhibitor, gefitinib. Additionally, the ST3GAL6 level was positively regulated by ST3GAL6-AS1, an antisense long non-coding RNA to its host gene. The downregulation of ST3GAL6-AS1 also heralds a worse prognosis in LUAD patients and promotes LUAD cell invasiveness, recapitulating the function of its host gene, ST3GAL6. Altogether, ST3GAL6-AS1-regulated ST3GAL6 is a frequently downregulated sialyltransferase in LUAD patients and negatively regulates EGFR signaling, which can serve as a promising independent prognostic marker in LUAD patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available